RhoA基因沉默对肝癌HepG2细胞增殖和迁移能力的影响

目的 构建RhoA-siRNA表达载体,研究其对肝癌HepG2细胞肿瘤生物学行为的影响.方法 利用pGenesil-1 质粒构建RhoA-siRNA表达载体,以脂质体法转染至肝癌HepG2细胞中建立稳定细胞系,并分为3组.转染 pGenesil-1-RhoA-siRNA 载体者为HepG2/RhoA-siRNA组,转染随机对照载体者为HepG2/control组,未转染的肝癌HepG2细胞作为HepG2组.Western blot检测RhoA-siRNA对其蛋白表达的抑制情况.分别采用MTT法、细胞划痕损伤和平板克隆形成实验检测转染细胞的增殖、迁移和生长潜能,流式细胞仪检测细胞周期变化.采用单凶素方差分析、x2检验比较各组差异.结果 3组细胞蛋白表达水平比较,HepG2/RhoA-siRNA组RhoA蛋白的表达明显下调(F=178.19,P<0.05).HepG2/control组和HepG2组细胞划痕损伤在48 h内愈合,而HepG2/RhoA-siRNA组则不能愈合.HepG2/RhoA-siRNA组克隆形成率低于HepG2组和HepG2/control组,分别为39%±3%、67%±5%、70%±6%,其差异有统计学意义(χ2=33.34,38.69,P<0.05).RhoA基因沉默显著抑制肝癌HepG2细胞的增殖,细胞周期中G0/G1期细胞数量增多而S期细胞数量减少(F=70.46,76.57,P<0.05).结论 RhoA-siRNA表达载体能抑制肝癌HepG2细胞的增殖和迁移,可为肝癌的基因治疗提供新的方法.

Effect of RhoA gene silencing on proliferation and migration of HepG2 cells

Objective To construct a RhoA-siRNA expression vector and determine its role on the malig-nant behavior of HepG2 cells.Methods A RhoA-siRNA DNA fragment was synthesized and cloned into the expression vector of pGenesil-1.The constructed Rhon-siRNA DNA plasmid was stably transfected into HerG2 cells by lipofectamine,and then HepG2 cells were divided into the HepG2/RhoA-siRNA group (HepG2 cells were transfected with pGenesil-1-RhoA-siRNA),HepG2/control group(HepG2 cells were transfected with control plasmid) and HepG2 group (without plasmid transfection).The inbibitory effect of RhoA-siRNA on RhoA protein expression was shown by Western blot.The proliferation,migration,growth potentiality and cell cycle of transfected HepG2 cells were evaluated by MTT assay,wounded healing,the plate cloning formation test and flow cytometry,respectively.All data were analyzed by one-way analysis of variance (ANOVA) and chi-square test.Results The expression of RhoA protein in the HepG2/RhoA-siRNA group was,significantly decreased compared with that in the other two groups (F=178.19,P<0.05).Scratched cells were healed within 48 hours in the HepG2/control group and HepG2 group,but not in the HepG2/RhoA-siRNA group.The clone formation rates in the HepG2/RhoA-siRNA group,HepG2 group and HepG2/control group were 39%±3%,67%±5%and 70%±6%,respectively,with a significant difference among the three groups(χ2=33.34,38.69,P<0.05).Flow cytometry showed that the number of cells transfected with RhoA-siRNA was highest in the G0/G1 phase and lowest in the S phase(F=70.46,76.57.P<0.05).Conclusion The RhoA-siRNA expression vector can effectively suppress the proliferation and migration of HepG2 cells,which may provide a novel gene therapy for hepatocellular carcinoma.